Rob Barrows
PersonHeard in 1 episode across 1 show since Apr 2026
Robert Barrow is a biotechnology executive and the chief executive officer of Definium Therapeutics, formerly MindMed, which develops treatments for brain-health disorders.
Episodes
First heard
Guest appearances
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 1 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
Email alert
Email me when Rob Barrows comes up on a podcast
One email a week at most, with the new episodes that mention Rob Barrows. Free, no account needed, unsubscribe in one click.
What Rob Barrows has said on podcasts
5 statements
About half of patients achieved remission 12 weeks after a single dose.
“12 weeks later, about half of patients were in clinical remission.”
Open the episode · Mad Money w/ Jim Cramer 4/20/26Listen at 29:12
A single monitored dose produces months of response and remission for most patients.
“A single dose of drug in a monitored clinical setting. And then we see months of clinical response and remission in a majority of patients.”
Open the episode · Mad Money w/ Jim Cramer 4/20/26Listen at 29:43
The voucher could reduce breakthrough-drug FDA review from six months to one or two.
“It takes that from even for breakthrough products, it's a six month review cycle and tries to bring that down to one or two months.”
Open the episode · Mad Money w/ Jim Cramer 4/20/26Listen at 33:00
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
1 episode featuring Rob Barrows, newest first
